Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gavocabtagene autoleucel |
Synonyms | |
Therapy Description |
Gavocabtagene autoleucel are T cells engineered to express an anti-mesothelin (MSLN) antibody linked to a CD3 epsilon subunit, with potential activity against MSLN-expressing tumors (Cancer Res 2021;81(13_Suppl):Abstract nr CT105). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gavocabtagene autoleucel | Gavo-cel|TC 210|TC-210|TC210 | MSLN Antibody 12 | Gavocabtagene autoleucel are T cells engineered to express an anti-mesothelin (MSLN) antibody linked to a CD3 epsilon subunit, with potential activity against MSLN-expressing tumors (Cancer Res 2021;81(13_Suppl):Abstract nr CT105). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |